Idiopathic intracranial hypertension
ICD-10 G93.2 · ICD-11 8D60.Y

What to Do When Idiopathic Intracranial Hypertension Does Not Respond to First-Line Medical Treatment

This protocol applies to patients with idiopathic intracranial hypertension (IIH) in whom first-line medical management has been attempted but has not achieved the required clinical outcomes.

First-Line Treatment and Failure Condition

Standard initial management combines weight loss with pharmacologic therapy — primarily acetazolamide, or alternatives such as topiramate, zonisamide, methazolamide, furosemide, and related diuretics in patients who cannot tolerate acetazolamide's side effects.

Escalation trigger

This next-line protocol is indicated when the above measures have not achieved improvement of papilledema, reduction of intracranial pressure, or resolution of IIH.

Next-Line Approach

When medical management has not achieved the treatment targets, surgical interventions aimed at relieving pressure on the optic nerve and preventing permanent visual loss may be considered — the full protocol specifies the options and clinical decision criteria.

Treatment Goals

References

  • In cases of refractory IIH or vision-threatening IIH, surgical options may be considered to relieve pressure on the optic nerve and to prevent permanent visual loss.
  • Ventriculoperitoneal shunting can be effective in preserving vision and reducing headaches, but failure has been reported in up to 18.7% of patients.
  • Optic nerve sheath fenestration (ONSF) involves making incisions in the sheath surrounding the optic nerve to allow drainage of CSF from the subarachnoid space, thereby reducing pressure on the nerve.
  • Venous sinus stenting is the placement of a stent in one or more of the stenotic venous sinuses, typically the distal transverse or sigmoid sinus.
  • A lumbar drain can be used as a temporizing measure to lower ICP rapidly in patients who present with severe symptoms, including visual loss.
  • Some evidence suggests that unilateral ONSF can improve papilledema in both eyes.
View source ↗